PDB29 A COST-UTILITY ANALYSIS OF SODIUM-GLUCOSE COTRANSPORTER (SGLT) 2 INHIBITORS IN ADDITION TO BASAL-BOLUS INSULIN IN THE TREATMENT OF TYPE 1 DIABETES IN THE USA USING THE PRIME DIABETES MODEL
Abstract
Authors
R. Pollock W.J. Valentine